RxDoctor Payments Data

Jeffrey Zibell, MD

Internal Medicine · Linthicum Heights, MDNPI 1275503997

Payments from drug & device makers

$306in general payments, 2019–2025

Across 10 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$212
  • Sunovion Pharmaceuticals Inc.$63
  • Novartis$15
  • Otsuka America Pharmaceutical, Inc.$15

What the payments were for

  • Food & beverage$29195%
  • Education$155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$322,390
Medicare patients
616
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban930$275,155
JardianceEmpagliflozin231$64,868
XareltoRivaroxaban167$52,431
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$46,601
MyrbetriqMirabegron162$38,187
RytaryCarbidopa/Levodopa17$37,278
OzempicSemaglutide26$25,219
LinzessLinaclotide43$24,837
ProcritEpoetin Alfa34$19,283
Atorvastatin Calcium1,450$18,274
JanuviaSitagliptin Phosphate38$17,608
CreonLipase/Protease/Amylase17$15,901
GemtesaVibegron50$15,519
Duloxetine Hcl377$14,449
TradjentaLinagliptin47$12,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$8,53035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Linthicum Heights

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →